|
1
|
Li Z, You Y, Griffin N, Feng J and Shan F:
Low-dose naltrexone (LDN): A promising treatment in immune-related
diseases and cancer therapy. Int Immunopharmacol. 61:178–184. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu WM, Scott KA, Dennis JL, Kaminska E,
Levett AJ and Dalgleish AG: Naltrexone at low doses upregulates a
unique gene expression not seen with normal doses: Implications for
its use in cancer therapy. Int J Oncol. 49:793–802. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Milligan G: G protein-coupled receptor
hetero-dimerization: Contribution to pharmacology and function. Br
J Pharmacol. 158:5–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nieto Gutierrez A and McDonald PH: GPCRs:
Emerging anti-cancer drug targets. Cell Signal. 41:65–74. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanchez-Vega F, Mina M, Armenia J, Chatila
WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia
S, et al: Oncogenic signaling pathways in the cancer genome atlas.
Cell. 173:321–337.e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arzimanoglou A, Brandl U, Cross JH,
Gil-Nagel A, Lagae L, Landmark CJ, Specchio N, Nabbout R, Thiele
EA, Gubbay O, et al: Epilepsy and cannabidiol: A guide to
treatment. Epileptic Disord. 22:1–14. 2020.PubMed/NCBI
|
|
7
|
Massi P, Solinas M, Cinquina V and
Parolaro D: Cannabidiol as potential anticancer drug. Br J Clin
Pharmacol. 75:303–312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McPartland JM, Glass M and Pertwee RG:
Meta-analysis of cannabinoid ligand binding affinity and receptor
distribution: Interspecies differences. Br J Pharmacol.
152:583–593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shahbazi F, Grandi V, Banerjee A and Trant
JF: Cannabinoids and cannabinoid receptors: The story so far.
iScience. 23:1013012020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shamas-Din A, Kale J, Leber B and Andrews
DW: Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb
Perspect Biol. 5:a0087142013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adams JM and Cory S: Bcl-2-regulated
apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol.
19:488–496. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hardwick JM and Soane L: Multiple
functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol.
5:a0087222013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Lu Z and Zhao X: Targeting Bcl-2
for cancer therapy. Biochim Biophys Acta Rev Cancer.
1876:1885692021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shrivastava A, Kuzontkoski PM, Groopman JE
and Prasad A: Cannabidiol induces programmed cell death in breast
cancer cells by coordinating the cross-talk between apoptosis and
autophagy. Mol Cancer Ther. 10:1161–1172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu WM, Fowler DW, Smith P and Dalgleish
AG: Pre-treatment with chemotherapy can enhance the antigenicity
and immunogenicity of tumours by promoting adaptive immune
responses. Br J Cancer. 102:115–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scott KA, Dalgleish AG and Liu WM:
Anticancer effects of phytocannabinoids used with chemotherapy in
leukaemia cells can be improved by altering the sequence of their
administration. Int J Oncol. 51:369–377. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scott KA, Shah S, Dalgleish AG and Liu WM:
Enhancing the activity of cannabidiol and other cannabinoids in
vitro through modifications to drug combinations and treatment
schedules. Anticancer Res. 33:4373–4380. 2013.PubMed/NCBI
|
|
19
|
Liubchenko K, Kordbacheh K, Khajehdehi N,
Visnjevac T, Ma F, Khan JS, Storey M, Abd-Elsayed A and Visnjevac
O: Naltrexone's impact on cancer progression and mortality: A
systematic review of studies in humans, animal models, and cell
cultures. Adv Ther. 38:904–924. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Cancer Institute, .
PDQ® integrative, alternative and complementary
therapies editorial board. Cannabis and cannabinoids
(PDQ®): Health professional version. 2021 Jun 3. PDQ
Cancer Information Summaries. National Cancer Institute (US);
Bethesda, MD: 2002, https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdqOctober
15–2021PubMed/NCBI
|
|
21
|
Viudez-Martínez A, García-Gutiérrez MS,
Fraguas-Sánchez AI, Torres-Suárez AI and Manzanares J: Effects of
cannabidiol plus naltrexone on motivation and ethanol consumption.
Br J Pharmacol. 175:3369–3378. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rios C, Gomes I and Devi LA: mu Opioid and
CB1 cannabinoid receptor interactions: Reciprocal inhibition of
receptor signaling and neuritogenesis. Br J Pharmacol. 148:387–395.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kovalchuk O and Kovalchuk I: Cannabinoids
as anticancer therapeutic agents. Cell Cycle. 19:961–989. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qu N, Meng Y, Handley MK, Wang C and Shan
F: Preclinical and clinical studies into the bioactivity of
low-dose naltrexone (LDN) for oncotherapy. Int Immunopharmacol.
96:1077142021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu WM, Fowler DW and Dalgleish AG:
Cannabis-derived substances in cancer therapy-an emerging
anti-inflammatory role for the cannabinoids. Curr Clin Pharmacol.
5:281–287. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Manzanares J, Ortiz S, Oliva JM,
Pérez-Rial S and Palomo T: Interactions between cannabinoid and
opioid receptor systems in the mediation of ethanol effects.
Alcohol Alcohol. 40:25–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bushlin I, Gupta A, Stockton SD Jr, Miller
LK and Devi LA: Dimerization with cannabinoid receptors
allosterically modulates delta opioid receptor activity during
neuropathic pain. PLoS One. 7:e497892012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Allouche S, Noble F and Marie N: Opioid
receptor desensitization: Mechanisms and its link to tolerance.
Front Pharmacol. 5:2802014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lohse MJ and Hofmann KP: Spatial and
temporal aspects of signaling by G-protein-coupled receptors. Mol
Pharmacol. 88:572–578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sever R and Brugge JS: Signal transduction
in cancer. Cold Spring Harb Perspect Med. 5:a0060982015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu F, Yang X, Geng M and Huang M:
Targeting ERK, an achilles' heel of the MAPK pathway, in cancer
therapy. Acta Pharm Sin B. 8:552–562. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Howlett AC: Cannabinoid receptor
signaling. Handb Exp Pharmacol. 168:53–79. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mebratu Y and Tesfaigzi Y: How ERK1/2
activation controls cell proliferation and cell death: Is
subcellular localization the answer? Cell Cycle. 8:1168–1175. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Go YY, Kim SR, Kim DY, Chae SW and Song
JJ: Cannabidiol enhances cytotoxicity of anti-cancer drugs in human
head and neck squamous cell carcinoma. Sci Rep. 10:206222020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Seltzer ES, Watters AK, MacKenzie D Jr,
Granat LM and Zhang D: Cannabidiol (CBD) as a promising anti-cancer
drug. Cancers (Basel). 12:32032020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pagano C, Navarra G, Coppola L, Bifulco M
and Laezza C: Molecular mechanism of cannabinoids in cancer
progression. Int J Mol Sci. 22:36802021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma M, Wang X, Liu N, Shan F and Feng Y:
Low-dose naltrexone inhibits colorectal cancer progression and
promotes apoptosis by increasing M1-type macrophages and activating
the Bax/Bcl-2/caspase-3/PARP pathway. Int Immunopharmacol.
83:1063882020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sharma V and McNeill JH: To scale or not
to scale: The principles of dose extrapolation. Br J Pharmacol.
157:907–921. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kleckner AS, Kleckner IR, Kamen CS, Tejani
MA, Janelsins MC, Morrow GR and Peppone LJ: Opportunities for
cannabis in supportive care in cancer. Ther Adv Med Oncol.
11:17588359198663622019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cant R, Dalgleish AG and Allen RL:
Naltrexone inhibits IL-6 and TNFα production in human immune cell
subsets following stimulation with ligands for intracellular
toll-like receptors. Front Immunol. 8:8092017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dalgleish A and Liu W: Chapter 9-cancer.
The LDN book: How a little-known generic drug-Low Dose
Naltrexone-could revolutionize treatment for autoimmune diseases,
cancer, autism, depression and more. Elsegood L: Chelsea Green
Publishing; London: pp. 143–151. 2016
|
